Tuberculosis innovations mean little if they cannot save lives

eLife

Volumn 6, Issue , 2017, Pages

  Pai, Madhukar ^a,b   Furin, Jennifer ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MANIPAL UNIVERSITY   (India)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; LIPOARABINOMANNAN; TUBERCULOSTATIC AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE ELIMINATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PERSONNEL; HUMAN; MIDDLE INCOME COUNTRY; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; RAPID TEST; SENSITIVITY ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; DIAGNOSTIC TEST; HEALTH CARE DELIVERY; PROCEDURES; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DIAGNOSTIC TESTS, ROUTINE; HEALTH SERVICES ACCESSIBILITY; HUMANS; TUBERCULOSIS;

EID: 85018902264     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.25956.001     Document Type: Article

References (58)

1. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D’Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, et al. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Medicine 9:e1001300. doi: 10.1371/journal.pmed.1001300, PMID: 22952439
2. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. 2016. Development, roll- out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? European Respiratory Journal 48:516–525. doi: 10.1183/13993003.00543-2016, PMID: 27418550
3. Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, Hayrapetyan A, Themba D, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F. 2016. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. The International Journal of Tuberculosis and Lung Disease 20:177–186. doi: 10.5588/ijtld.15.0962, PMID: 26792469
4. Cazabon D, Alsdurf H, Satyanarayana S, Nathavitharana R, Subbaraman R, Daftary A, Pai M. 2017. Quality of Tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. International Journal of Infectious Diseases 56:111–116. doi: 10.1016/j.ijid.2016.10.016, PMID: 277 94468
5. Central TB Division. 2017. National Strategic Plan for Tuberculosis Elimination 2017–2025 (Draft) New Delhi: Ministry of Health & Family Welfare. Government of India. http://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf.
6. Chavan D. 2017. Fighting TB requires empowered patients. BMJ 356:i6344. doi: 10.1136/bmj.i6344, PMID: 28179263
7. Chihota VN, Ginindza S, McCarthy K, Grant AD, Churchyard G, Fielding K. 2015. Missed Opportunities for TB investigation in primary care clinics in South Africa: experience from the XTEND Trial. PLoS One 10:e0138149. doi: 10.1371/journal.pone.0138149, PMID: 26383102
8. Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, Erasmus LK, Ndjeka NO, Mvusi L, Vassall A, Sinanovic E, Cox HS, Dye C, Grant AD, Fielding KL. 2015. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. The Lancet Global Health 3:e450–e457. doi: 10.1016/S2214-109X(15)00100-X, PMID: 26187490
9. Clouse K, Blevins M, Lindegren ML, Yotebieng M, Nguyen DT, Omondi A, Michael D, Zannou DM, Carriquiry G, Pettit A, International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration. 2017. Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in the International epidemiologic databases to evaluate AIDS (IeDEA) program. PLoS One 12:e0171384. doi: 10.1371/journal.pone.0171384, PMID: 28182705
10. Das J, Kwan A, Daniels B, Satyanarayana S, Subbaraman R, Bergkvist S, Das RK, Das V, Pai M. 2015. Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study. The Lancet Infectious Diseases 15:1305–1313. doi: 10.1016/S1473-3099(15)00077-8, PMID: 26268690
11. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B, TMC207-C208 Study Group. 2014. Multidrug- resistant tuberculosis and culture conversion with bedaquiline. New England Journal of Medicine 371: 723–732. doi: 10.1056/NEJMoa1313865, PMID: 25140 958
12. DR-TB STAT. 2017. March 2017 Task Force Update. Stop TB Partnership. http://www.stoptb.org/wg/mdrtb/taskforces.asp?tf=4 [Accessed 27 March, 2017].
13. Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, Menezes A, Cobelens F. 2014. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster- randomized trial. PLoS Medicine 11:e1001766. doi: 10.1371/journal.pmed.1001766, PMID: 25490549
14. Engel N, Wachter K, Pai M, Gallarda J, Boehme C, Celentano I, Weintraub R. 2016. Addressing the challenges of diagnostics demand and supply: insights from an online global health discussion platform. BMJ Global Health 1:e000132. doi: 10.1136/bmjgh-2016-000132
15. Field SK, Fisher D, Jarand JM, Cowie RL. 2012. New treatment options for multidrug-resistant tuberculosis. Therapeutic Advances in Respiratory Disease 6:255–268. doi: 10.1177/1753465812452193, PMID: 22763676
16. FIND, McGill International TB Centre, UNITAID. 2015. TB Diagnostics Market in Select High-Burden Countries: Current Market and Future Opportunities For Novel Diagnostics. https://www.mcgill.ca/tb/files/tb/tb_diagnostics_market_in_select_high-burden_countries_current_market_and_future_opportunities_for_novel_diagnostics.pdf.
17. Floyd K, Fitzpatrick C, Pantoja A, Raviglione M. 2013. Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002-11, and requirements to meet 2015 targets. The Lancet Global Health 1:e105–e115. doi: 10.1016/S2214-109X(13)70032-9, PMID: 25104145
18. Furin J, Brigden G, Lessem E, Rich M, Vaughan L, Lynch S. 2016. Global progress and challenges in implementing new medications for treating multidrug- resistant tuberculosis. Emerging Infectious Diseases 22. doi: 10.3201/eid2203.151430, PMID: 26885674
19. Furin J, Diacon AH, Andries K. 2017. Combating drug- resistant tuberculosis: the unexpected benefits of bedaquiline. The International Journal of Tuberculosis and Lung Disease 21:4–5. doi: 10.5588/ijtld.16.0768, PMID: 28157457
20. Furin J, Mafukidze A, Brigden G, du Cros P, Golin R, Harausz E, Seddon JA, Ustero P, Garcia-Prats AJ. 2015. A bitter pill to swallow: the need for better medications for drug-resistant tuberculosis in children. The International Journal of Tuberculosis and Lung Disease 19 Suppl 1:55–60. doi: 10.5588/ijtld.15.0380, PMID: 26564544
21. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, et al. 2012. Delamanid for multidrug-resistant pulmonary tuberculosis. New England Journal of Medicine 366:2151–2160. doi: 10.1056/NEJMoa1112433, PMID: 22670901
22. Gotham D, Fortunak J, Pozniak A, Khoo S, Cooke G, Nytko FE, Hill A. 2017. Estimated generic prices for novel treatments for drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 72:dkw522. doi: 10.1093/jac/dkw522
23. Guglielmetti L, Hewison C, Avaliani Z, Hughes J, Kiria N, Lomtadze N, Ndjeka N, Setkina S, Shabangu A, Sikhondze W, Skrahina A, Veziris N, Furin J. 2017. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. The International Journal of Tuberculosis and Lung Disease 21:167–174. doi: 10.5588/ijtld.16.0493, PMID: 28234080
24. Hanrahan CF, Dorman SE, Erasmus L, Koornhof H, Coetzee G, Golub JE. 2012. The impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: an observational cohort study. PLoS One 7:e49898. doi: 10.1371/journal.pone.0049898, PMID: 23226229
25. Kik SV, Denkinger CM, Chedore P, Pai M. 2014. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? European Respiratory Journal 43:1793–1796. doi: 10.1183/09031936.00217313, PMID: 24525440
26. Kirby T. 2017. Landmark legal ruling sees Indian girl prescribed bedaquiline for XDR-TB. The Lancet Respiratory Medicine 5:249. doi: 10.1016/S2213-2600(17)30042-5, PMID: 28169199
27. Lessem E, Cox H, Daniels C, Furin J, McKenna L, Mitnick CD, Mosidi T, Reed C, Seaworth B, Stillo J, Tisile P, von Delft D. 2015. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. International Journal of Infectious Diseases 32:56–60. doi: 10.1016/j.ijid.2014.12.012, PMID: 25809757
28. Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesseling A, How C, Jean-Philippe P, Lessem E, Makhene M, Mbelle N, Marais B, McIlleron H, McNeeley DF, Mendel C, Murray S, et al. 2015. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. The Lancet Infectious Diseases 15:711–720. doi: 10.1016/S1473-3099(15)00007-9, PMID: 25957923
29. Naidoo P, du Toit E, Dunbar R, Lombard C, Caldwell J, Detjen A, Squire SB, Enarson DA, Beyers N. 2014. A comparison of multidrug-resistant tuberculosis treatment commencement times in MDRTBPlus line probe assay and XpertÒ MTB/RIF-based algorithms in a routine operational setting in Cape Town. PLoS One 9:e103328. doi: 10.1371/journal.pone.0103328, PMID: 25079599
30. Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, Ferreira H, Maartens G, Mametja D, Meintjes G, Padanilam X, Variava E, Pym A, Pillay Y. 2015. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. The International Journal of Tuberculosis and Lung Disease 19:979–985. doi: 10.5588/ijtld.14.0944, PMID: 26162365
31. Ndjeka N. 2016. Incorporation of bedaquiline in the South African National TB program. Abstract Number 754. 2016 Conference on Retroviruses and Opportunistic Infections, Boston, USA.
32. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. 2016. Tuberculosis. Nature Reviews Disease Primers 2: 16076–23. doi: 10.1038/nrdp.2016.76, PMID: 27784 885
33. Pai M, Bhaumik S, Bhuyan SS. 2017. India’s plan to eliminate tuberculosis by 2025: converting rhetoric into reality. BMJ Global Health 2:e000326. doi: 10.1136/bmjgh-2017-000326
34. Pai M, Schito M. 2015. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. Journal of Infectious Diseases 211 Suppl 2:S21–S28. doi: 10.1093/infdis/jiu803, PMID: 25765103
35. Puri L, Oghor C, Denkinger CM, Pai M. 2016. Xpert MTB/RIF for Tuberculosis testing: access and price in highly privatised health markets. The Lancet Global Health 4:e94–e95. doi: 10.1016/S2214-109X(15)00269-7, PMID: 26823226
36. Qin ZZ, Pai M, Van Gemert W, Sahu S, Ghiasi M, Creswell J. 2015. How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? European Respiratory Journal 45:549–554. doi: 10.1183/09031936.00147714, PMID: 25359338
37. Raizada N, Sachdeva KS, Nair SA, Kulsange S, Gupta RS, Thakur R, Parmar M, Gray C, Ramachandran R, Vadera B, Ekka S, Dhawan S, Babre A, Ghedia M, Alavadi U, Dewan P, Khetrapal M, Khanna A, Boehme C, Paramsivan CN. 2014. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB. PLoS One 9:e105346. doi: 10.1371/journal.pone.0105346, PMID: 25140877
38. RESIST TB. 2017. Research excellence to stop TB resistance. Clinical trials progress report. Resist-TB. http://www.resisttb.org/?page_id=1602 [Accessed 27 March, 2017].
39. Sachdeva KS, Raizada N, Sreenivas A, Van’t Hoog AH, van den Hof S, Dewan PK, Thakur R, Gupta RS, Kulsange S, Vadera B, Babre A, Gray C, Parmar M, Ghedia M, Ramachandran R, Alavadi U, Arinaminpathy N, Denkinger C, Boehme C, Paramasivan CN. 2015. Use of Xpert MTB/RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India. PLoS One 10:e0126065. doi: 10.1371/journal.pone.0126065, PMID: 25996389
40. Sreeramareddy CT, Qin ZZ, Satyanarayana S, Subbaraman R, Pai M. 2014. Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. The International Journal of Tuberculosis and Lung Disease 18:255–266. doi: 10.5588/ijtld.13.0585, PMID: 24670558
41. Subbaraman R, Nathavitharana R, Satyanarayana S, Pai M, Thomas B, Chaddha V, Rade K, Swaminathan S, Mayer K. 2016. The tuberculosis cascade of care in India’s public sector: recent estimates and gaps in knowledge. PLoS Medicine 13:e1002149. doi: 10.1371/journal.pmed.1002149
42. The Lancet. 2017. Health in India, 2017. Lancet 389: 127. doi: 10.1016/S0140-6736(17)30075-2, PMID: 2 8102123
43. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K, 2014. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. The Lancet 383:424–435. doi: 10.1016/S0140-6736(13)62073-5
44. Udwadia ZF, Ganatra S, Mullerpattan JB. 2017. Compassionate use of bedaquiline in highly drug- resistant tuberculosis patients in Mumbai, India. European Respiratory Journal 49:1601699. doi: 10.1183/13993003.01699-2016, PMID: 28331036
45. Weld E, Garcia-Prats AJ, Furin J, Bailey T, Hesseling AC, Dooley K. 2017. The time has come: the case for injectable-sparing regimens in children with multidrug- resistant tuberculosis. The Lancet. Respiratory Medicine 5:245–246. doi: 10.1016/S2213-2600(17)30078-4
46. World Health Organization. 2007. The Use of Liquid Medium for Culture and DST. Geneva, Switzerland: World Health Organization. http://www.who.int/tb/laboratory/policy_liquid_medium_for_culture_dst/en/index.html.
47. World Health Organization. 2013a. Policy Update: Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children. Geneva, Switzerland: World Health Organization.
48. World Health Organization. 2013b. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva, Switzerland: World Health Organization.
49. World Health Organization. 2014a. Guidelines on the Management of Latent Tuberculosis Infection. WHO/HTM/TB/2015.01. Geneva, Switzerland: World Health Organization.
50. World Health Organization. 2014b. The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva, Switzerland: World Health Organization.
51. World Health Organization. 2015a. The Use of Lateral Flow Urine Lipoarabinomannan Assay (LF-LAM) for the Diagnosis and Screening of Active Tuberculosis in People Living with HIV. Policy Update. Geneva, Switzerland: World Health Organization.
52. World Health Organization. 2015b. Active Tuberculosis Drug Safety Monitoring and Management (ADSM): A Framework for Implementation. WHO/HTM/TB/2015.28. Geneva, Switzerland: World Health Organization.
53. World Health Organization. 2016a. Global Tuberculosis Report 2016. Geneva, Switzerland: World Heath Organization.
54. World Health Organization. 2016b. The Use of Molecular Line Probe Assays for the Detection of Resistance to Second-Line Anti-Tuberculosis Drugs. Policy Guidance. Geneva, Switzerland: World Health Organization. http://www.who.int/entity/tb/areas-of-work/laboratory/WHOPolicyStatementSLLPA.pdf?ua=1.
55. World Health Organization. 2017a. WHO monitoring of Xpert MTB/RIF roll-out. http://www.who.int/tb/areas-of-work/laboratory/mtb-rif-rollout/en/[Accessed 9 February, 2017].
56. World Health Organization. 2017b. Report of the Guideline Development Group Meeting on the Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis, a Review of Available Evidence (2016). Geneva, Switzerland: World Health Organization. http://apps.who.int/iris/bitstream/10665/254712/1/WHO-HTM-TB-2017.01-eng.pdf?ua=1.
57. World Health Organization. 2017c. WHO Meeting Report of a Technical Expert Consultation: Non- Inferiority Analysis of Xpert MTB/RIF Ultra Compared to Xpert MTB/RIF. Geneva, Switzerland: World Health Organization. http://apps.who.int/iris/bitstream/10665/254792/1/WHO-HTM-TB-2017.04-eng.pdf.
58. World Health Organization. 2017d. Ethics guidance for the implementation of the end TB strategy. http://who.int/tb/publications/2017/ethics-guidance/en/[Accessed 28 March, 2017].